To our knowledge, this is the first clinical trial combining an allogenic whole‐cell vaccine with an immune checkpoint inhibitor in MMR‐p metastatic CRC, and was designed to test the hypothesis that a vaccine can modify an otherwise PD‐1 inhibitor insensitive cancer into a sensitive one. The gene discussed is PDCD1; the disease is cancer.